Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Strategy Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.31 (market cap $12.58B), while Strategy Inc. trades at $157.21 (market cap $60.40B). The key difference: Strategy Inc. is far larger — about 4.8× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Strategy Inc. for 112 Days on average.
| HALO | MSTR | |
|---|---|---|
Market Cap | $12.58B | $60.40B |
Volume | 2,179,278 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $115.22 | $320.29 |
52-Week Low | $61.63 | $82.31 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $14.49B | $79.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSTR trades at $151.89, down 0.96% on the day, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with a net income margin of -6,102.96% and three consecutive quarterly earnings misses. Despite negative profitability, analyst consensus remains bullish with a $253.36 price target, representing 67% upside potential from current levels. Recent news highlights Citigroup doubling its price target to $240 following a 35% monthly rally.
The outlook remains polarized between technical optimism and fundamental challenges. While technical indicators suggest continued momentum, the company's massive losses and negative cash flow from operations pose significant risks. Investors face the dilemma of strong Wall Street support against deteriorating financial performance, with the stock's fate closely tied to Bitcoin market movements despite being a traditional software company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
